<code id='7FC1DF7458'></code><style id='7FC1DF7458'></style>
    • <acronym id='7FC1DF7458'></acronym>
      <center id='7FC1DF7458'><center id='7FC1DF7458'><tfoot id='7FC1DF7458'></tfoot></center><abbr id='7FC1DF7458'><dir id='7FC1DF7458'><tfoot id='7FC1DF7458'></tfoot><noframes id='7FC1DF7458'>

    • <optgroup id='7FC1DF7458'><strike id='7FC1DF7458'><sup id='7FC1DF7458'></sup></strike><code id='7FC1DF7458'></code></optgroup>
        1. <b id='7FC1DF7458'><label id='7FC1DF7458'><select id='7FC1DF7458'><dt id='7FC1DF7458'><span id='7FC1DF7458'></span></dt></select></label></b><u id='7FC1DF7458'></u>
          <i id='7FC1DF7458'><strike id='7FC1DF7458'><tt id='7FC1DF7458'><pre id='7FC1DF7458'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:22829
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Eli Lilly reports tirzepatide MASH success during Q4 earnings
          Eli Lilly reports tirzepatide MASH success during Q4 earnings

          DarronCummings/APTheblockbusterweightlossanddiabetesdrugsoldbyEliLillyalsoappearstoimprovefattyliver

          read more
          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more

          Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

          CDCWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyour